Avalo Therapeutics Inc (NASDAQ: AVTX) stock closed at $13.02 on 9/29/25 after a major increase of 20.6%. Moreover, this advance was accompanied by exceptionally high trading volume at 934% of normal. The stock has been strong relative to the market over the last nine months and has risen 10.1% during the last week.
Current PriceTarget Research Rating
Avalo Therapeutics has a current Value Trend Rating of B (Positive). This rating combines consistent signals from two proprietary PTR measures of a stock's attractiveness. Avalo Therapeutics has a slightly positive Power Rating of 61 and a good Appreciation Score of 75, with the Positive Value Trend Rating the result.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of B. This review will be completed in the next several days.